Dr. Robert J. Horoshak, DDS in Duluth, Minnesota

Info
Map & Directions
  • No Records Found

    Sorry, no records were found. Please adjust your search criteria and try again.

    Google Map Not Loaded

    Sorry, unable to load Google Maps API.

  • Homestead Family Dental

  • Lakeside Dental

  • North Shore Dental Ltd

  • Mount Royal Dental

  • Camille Zelen, DDS

  • Mount Royal Dental

  • Aurora Sheboygan Prices – VORICONAZOLE 200 MG IV SOLR is $81.19

    At Aurora Medical Center Sheboygan, we prioritize providing our patients with comprehensive financial information upfront. For Charge Code 10002800, regarding VORICONAZOLE 200 MG IV SOLR, which is classified under revenue code 250 and associated with CPT code J3465, the designated fee stands at $81.19. Our aim through the CompareMedCosts program is to furnish you with all the details you need to make informed healthcare decisions, offering clarity and transparency around the costs associated with your care.

  • Aurora Sheboygan Prices – ATAZANVIR is $385

    At Aurora Medical Center Sheboygan, we prioritize providing our patients with comprehensive financial information upfront. For Charge Code 10006678, regarding ATAZANVIR, which is classified under revenue code 301 and associated with CPT code 80299, the designated fee stands at $385. Our aim through the CompareMedCosts program is to furnish you with all the details you need to make informed healthcare decisions, offering clarity and transparency around the costs associated with your care.

  • Aurora Sheboygan Prices – ONDANSETRON HCL 8 MG PO TABS is $8.44

    At Aurora Medical Center Sheboygan, we prioritize providing our patients with comprehensive financial information upfront. For Charge Code 10002800, regarding ONDANSETRON HCL 8 MG PO TABS, which is classified under revenue code 250 and associated with CPT code Q0162, the designated fee stands at $8.44. Our aim through the CompareMedCosts program is to furnish you with all the details you need to make informed healthcare decisions, offering clarity and transparency around the costs associated with your care.

  • FDA moves to tighten compounded GLP-1 access as shortage pressure eases

    The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from a list that helps some large compounding facilities legally make GLP-1 drugs from bulk ingredients. The agency says it did not find a clinical need for that pathway, and it is asking for public comments through June 29, 2026. For patients who rely on compounded GLP-1 medicines, the change could affect access, pricing, and refill planning—but it is not final yet.